- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01882452
A Randomised Controlled Clinical Trial of Memory Specificity Training (MEST) for Depression (MEST)
March 21, 2018 updated by: Professor Tim Dalgleish, Medical Research Council
Depression involves the tendency to recall overgeneral personal memories, a phenomenon which has been linked to numerous adverse psychological outcomes.
The purpose of this study is to investigate whether a group-based Memory Specificity Training (MEST) programme improves outcomes in depression, and how this compares to an education and support control group.
The primary aim is to examine whether MEST, which involves repeated practice retrieving specific autobiographical memories reduces depressive symptoms immediately post-treatment, and whether this is maintained 3 months after treatment.
The secondary objective of this trial is to examine the role of hypothesised cognitive processes (ie., rumination, executive control, cognitive avoidance) which may underlie improvements in depression and memory.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
60
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Sydney, Australia, 2022
- Aliza Werner-Seidler
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Principal diagnosis of Major Depressive Disorder
- History of more than one previous depressive episode
- Current diagnosis of a Major Depressive Episode
- Depressive symptoms rated in the mild-severe range (> 13 on the BDI-II)
- Memory specificity < .70 (as assessed on the AMT)
Exclusion Criteria:
- Head trauma
- Organic brain damage
- Secondary diagnosis of another affective disorder
- Psychosis
- Current drug or alcohol abuse or dependence
- A diagnosed Axis II disorder
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Memory Specificity Training
Five weekly one-hour sessions of memory specificity training administered in groups of 5-8 participants.
|
This intervention is a manualised, structured treatment delivered over 5 x 60 minute sessions to groups of 5-8 individuals.
This treatment involves repeated practice of retrieving specific autobiographical memories in response to positive, negative and neutral cue words.
There is a single psychoeducation component in the first session about memory difficulties common in depression which provides the rationale for this treatment.
The training is supplemented by weekly homework practice.
|
Active Comparator: Education and Support
Five weekly one-hour sessions of an education-and-discussion supportive intervention, administered in groups of 5-8 participants.
|
The education-and-support comparison condition is matched with the experimental arm for length and format (ie., 5 x 60 minute weekly sessions in groups of 5-8 individuals).
Groups receive a single psychoeducation component where information about depression is provided.
This is followed by non-directive support where participants are encouraged to raise different kinds of events that occur each week for discussion in the group.
The sessions are supplemented by a homework diary where participants will be invited to note down an event that occurs each day, which may be positive, negative, or benign and non-emotional in nature.
This material will provide the basis for discussion in the weekly group meetings.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in depressive symptoms on the Beck Depression Inventory II (BDI-II)
Time Frame: Change from baseline to 3 months post-treatment
|
Symptom severity score
|
Change from baseline to 3 months post-treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in depressive status according to the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders - IV (SCID-IV)
Time Frame: Change from baseline at end of treatment (approximately 6 weeks) and 3 months post-treatment, and 6-months post-treatment (6-month follow-up for MEST group only)
|
Presence of a current Major Depressive Episode (MDE)
|
Change from baseline at end of treatment (approximately 6 weeks) and 3 months post-treatment, and 6-months post-treatment (6-month follow-up for MEST group only)
|
Change from baseline in autobiographical memory specificity on Autobiographical Memory Test (AMT)
Time Frame: Change from baseline at end of treatment (approximately 6 weeks) and 3 months post-treatment
|
Memory specificity level
|
Change from baseline at end of treatment (approximately 6 weeks) and 3 months post-treatment
|
Change from baseline in depressive symptoms as measured on the BDI-II
Time Frame: Change from baseline to post-treatment (approximately 6-weeks)
|
Symptom severity score
|
Change from baseline to post-treatment (approximately 6-weeks)
|
Depression free days following treatment according to the Longitudinal Follow-up Evaluation on the SCID-IV
Time Frame: Post-treatment and 3-month and 6-month follow-up
|
Number of depression-free days
|
Post-treatment and 3-month and 6-month follow-up
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline on the Beck Anxiety Inventory (BAI)
Time Frame: Change from baseline at end of treatment (approximately 6 weeks) and 3 months post-treatment
|
Symptom severity score
|
Change from baseline at end of treatment (approximately 6 weeks) and 3 months post-treatment
|
Change from baseline on the Beck Hopelessness Scale (BHS)
Time Frame: Change from baseline at end of treatment (approximately 6 weeks) and 3 months post-treatment
|
Hopelessness score
|
Change from baseline at end of treatment (approximately 6 weeks) and 3 months post-treatment
|
Change from baseline on the Cognitive Avoidance Questionnaire (CAQ)
Time Frame: Change from baseline at end of treatment (approximately 6 weeks) and 3 months post-treatment
|
Tendency for avoidance score
|
Change from baseline at end of treatment (approximately 6 weeks) and 3 months post-treatment
|
Change in baseline on Rumination Response Scale (RRS)
Time Frame: Change from baseline at end of treatment (approximately 6 weeks) and 3 months post-treatment
|
Tendency to ruminate score
|
Change from baseline at end of treatment (approximately 6 weeks) and 3 months post-treatment
|
Change from baseline in performance on Means-Ends Problem Solving Task (MEPS)
Time Frame: Change from baseline at end of treatment (approximately 6 weeks) and 3 months post-treatment
|
Problem solving effectiveness score
|
Change from baseline at end of treatment (approximately 6 weeks) and 3 months post-treatment
|
Change from baseline in performance on Verbal Fluency Task
Time Frame: Change from baseline at end of treatment (approximately 6 weeks) and 3 months post-treatment
|
Index of executive control
|
Change from baseline at end of treatment (approximately 6 weeks) and 3 months post-treatment
|
Change in baseline on performance on Digit Span Task
Time Frame: Change from baseline at end of treatment (approximately 6 weeks) and 3 months post-treatment
|
Working memory index
|
Change from baseline at end of treatment (approximately 6 weeks) and 3 months post-treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Tim Dalgleish, PhD, Medical Research Council
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Werner-Seidler A, Hitchcock C, Bevan A, McKinnon A, Gillard J, Dahm T, Chadwick I, Panesar I, Breakwell L, Mueller V, Rodrigues E, Rees C, Gormley S, Schweizer S, Watson P, Raes F, Jobson L, Dalgleish T. A cluster randomized controlled platform trial comparing group MEmory specificity training (MEST) to group psychoeducation and supportive counselling (PSC) in the treatment of recurrent depression. Behav Res Ther. 2018 Jun;105:1-9. doi: 10.1016/j.brat.2018.03.004. Epub 2018 Mar 15.
- Dalgleish T, Bevan A, McKinnon A, Breakwell L, Mueller V, Chadwick I, Schweizer S, Hitchcock C, Watson P, Raes F, Jobson L, Werner-Seidler A. A comparison of MEmory Specificity Training (MEST) to education and support (ES) in the treatment of recurrent depression: study protocol for a cluster randomised controlled trial. Trials. 2014 Jul 22;15:293. doi: 10.1186/1745-6215-15-293.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2013
Primary Completion (Actual)
August 1, 2016
Study Completion (Actual)
October 1, 2016
Study Registration Dates
First Submitted
June 18, 2013
First Submitted That Met QC Criteria
June 18, 2013
First Posted (Estimate)
June 20, 2013
Study Record Updates
Last Update Posted (Actual)
March 22, 2018
Last Update Submitted That Met QC Criteria
March 21, 2018
Last Verified
March 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MEST-UK
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depressive Symptoms
-
Julia EderNot yet recruitingDepressive Disorder | Depression | Depressive Symptoms | Major Depressive Disorder | Depressive EpisodeGermany
-
Dr. Nazanin AlaviCompletedDepression | Depressive Symptoms | Major Depressive DisorderCanada
-
Linkoeping UniversityCompletedMajor Depressive DisorderSweden
-
The University of Texas Health Science Center at...TerminatedDepression | Major Depressive DisorderUnited States
-
Santa Casa Medical SchoolFaculdade de Ciências Médicas da Santa Casa de São PauloUnknownDepressive SymptomsBrazil
-
Massachusetts General HospitalCompletedMajor Depressive DisorderUnited States, China
-
State University of New York at BuffaloCompletedDepressive Symptoms | Major Depressive Disorder, Recurrent, in RemissionUnited States
-
University of TorontoKaiser Permanente; University of Colorado, BoulderCompletedDepressive Symptoms | Major Depressive Disorder, Recurrent, in RemissionUnited States
-
Tonix Pharmaceuticals, Inc.Rho, Inc.CompletedDepressive Disorder | Depression | Depressive Symptoms | Depressive Disorder, Major | Depressive Episode | Depression SevereUnited States
-
University of PittsburghCompleted
Clinical Trials on Memory Specificity Training
-
University of ValenciaNot yet recruitingControl Group | Training Group
-
Centre de Recherche de l'Institut Universitaire...Canadian Institutes of Health Research (CIHR); Natural Sciences and Engineering...Recruiting
-
Johns Hopkins UniversityTerminatedSubstance-Related DisordersUnited States
-
Icahn School of Medicine at Mount SinaiCompletedDepression | Generalized Anxiety Disorder | Bipolar Disorder | Major Depressive Disorder | Social Phobia | Post-traumatic Stress DisorderUnited States
-
Henry Ford Health SystemNot yet recruiting
-
University of GeorgiaRecruitingSchizophrenia | Schizo Affective DisorderUnited States
-
Milwaukee VA Medical CenterCompletedPosttraumatic Stress DisorderUnited States
-
University of CalgaryBrain & Behavior Research FoundationTerminatedPsychotic Disorders
-
VA Office of Research and DevelopmentUniversity of MarylandCompleted
-
Radboud University Medical CenterNetherlands Organisation for Scientific ResearchCompletedAttention Deficit Disorder With HyperactivityNetherlands